We found no direct association between circulating DBP levels and bladder cancer risk (P-trend=0.83).
We found no direct association between circulating DBP and risk of bladder cancer; however, the inverse association between total serum 25(OH D and bladder cancer risk appeared limited to men with lower DBP levels.
There was an inverse association between the molar ratio of 25(OH D:DBP, a proxy for free circulating 25(OH D, and risk of bladder cancer that was similar in magnitude to that for total circulating 25(OH D, although it was not statistically significant (P-trend=0.08; Table 2).
Our findings provide additional support for an aetiologic role for vitamin D in bladder cancer and suggest that free, rather than total, circulating vitamin D may be a more relevant exposure when examining bladder and, perhaps, other cancers.
The diagnostic value and prognostic significance of circulating tumor cell (CTC) detection in patients with bladder cancer is controversial.
We conducted a nested case control study within the ATBC Study to examine whether circulating DBP was prospectively associated with risk of bladder cancer, and whether it modified the previously reported protective association between higher circulating 25(OH D and risk of bladder cancer (Mondul et al, 2010).
Our findings provide additional support for the hypothesis that vitamin D may have an aetiologic role in the prevention of bladder cancer, and suggest that free, rather than total, circulating vitamin D may be a more specific and relevant measure of vitamin D exposure when examining bladder cancer and, perhaps, other cancer outcomes.
Today, studies on the concentration of fragments of circulating cell-free DNA and their respective sizes in patients with bladder cancer are not plentiful in the literature.
These findings suggest that higher concentrations of free circulating 25(OH D may be more biologically relevant to risk of bladder cancer than total 25(OH D.
Preliminary research has suggested the potential prognostic value of circulating tumor cells (CTC) in patients with advanced nonmetastatic urothelial carcinoma of the bladder (UCB).
To examine whether the circulating TIMP-2 or MMP-2 TIMP-2 coMMP-2 TIMP-2ate with disease-free or complexpecific survivassociatedder cancer patients.
